NeoGenomics, Inc. (NASDAQ:NEO) is First Light Asset Management LLC’s 7th Largest Position

First Light Asset Management LLC grew its position in NeoGenomics, Inc. (NASDAQ:NEO) by 3.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,167,585 shares of the medical research company’s stock after purchasing an additional 91,030 shares during the period. NeoGenomics accounts for about 5.0% of First Light Asset Management LLC’s portfolio, making the stock its 7th biggest position. First Light Asset Management LLC’s holdings in NeoGenomics were worth $52,202,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Nordea Investment Management AB grew its stake in NeoGenomics by 2.8% during the 4th quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock worth $1,301,000 after buying an additional 2,125 shares during the last quarter. Swiss National Bank grew its stake in shares of NeoGenomics by 1.0% during the fourth quarter. Swiss National Bank now owns 252,100 shares of the medical research company’s stock worth $4,155,000 after acquiring an additional 2,600 shares during the last quarter. Jennison Associates LLC grew its stake in shares of NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company’s stock worth $24,963,000 after acquiring an additional 238,288 shares during the last quarter. Rhumbline Advisers raised its position in shares of NeoGenomics by 2.4% in the 4th quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company’s stock valued at $6,411,000 after purchasing an additional 9,098 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in NeoGenomics by 2.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,161,352 shares of the medical research company’s stock worth $19,139,000 after purchasing an additional 26,701 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on NEO shares. Needham & Company LLC cut their price target on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Piper Sandler cut their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Bank of America decreased their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. Finally, The Goldman Sachs Group decreased their price objective on shares of NeoGenomics from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.30.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $10.27 on Monday. The company has a market capitalization of $1.32 billion, a PE ratio of -16.56 and a beta of 1.41. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The company’s fifty day moving average price is $9.80 and its 200 day moving average price is $13.48. NeoGenomics, Inc. has a 1 year low of $8.05 and a 1 year high of $19.12.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $173.40 million. On average, research analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.